The E100: Extending runways, dumping drugs, factoring in a banking crisis and grappling with the IRA — there's a lot for biotech execs to deal with
If there’s one major theme playing out in biotech this year, it’s watching out for the pitfalls. And then getting hit out of left field …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.